Testmaxxing: the testosterone-optimisation trend versus the trial evidence

Testmaxxing — also "hormonemaxxing" — is the drive to push testosterone as high as possible, on the belief that more of the hormone means more muscle, drive, confidence and status. In practice it runs along two tracks: over-the-counter "natural test boosters", and a fast-growing direct-to-consumer pipeline that will prescribe testosterone online. The first is mostly ineffective. The second can be genuinely useful for men who are actually deficient and genuinely harmful for men who are not — and the trend is built to blur which is which.

This is standing informational reporting, not medical advice. Testosterone is a prescription drug and its use is a clinical decision.

The "natural booster" track

The supplement half of testmaxxing has been directly tested and comes up short. A study evaluating 50 "testosterone booster" supplements found that 90% claimed to boost testosterone, 50% to improve libido and 48% to help users "feel stronger" — across 109 unique ingredients, averaging 8.3 per product [s3]. When the authors searched the published literature for support, only about a quarter of the supplements (24.8%) had any data showing an increase in testosterone at all, and several components exceeded recommended intake levels [s3]. The category sells the promise, not the effect. Our broader coverage of testosterone therapy and the trial evidence sets out what genuinely moves the hormone, which these products largely do not.

Worth noting alongside this is that population testosterone levels have drifted down over generations even after adjusting for age and weight — a real phenomenon the trend cites as justification, and one we cover in the generational testosterone decline. A downward population trend is not the same as an individual deficiency requiring treatment, and the slippage between the two is where testmaxxing does its persuading.

The direct-to-consumer TRT track

The more consequential track is the online-clinic pipeline. A global content analysis of 253 websites selling testosterone treatment found that many operate at a distance from clinical guidelines: about a quarter (24.4%) routinely used non-guideline-based practices, and the authors noted that testosterone prescribing has increased up to 12-fold in some settings over two decades [s4]. Our piece on direct-to-consumer testosterone clinics details how those services frame eligibility to widen it.

The clinical evidence for testosterone therapy is real but narrow. The Testosterone Trials assigned 790 men aged 65 or older with low measured testosterone and symptoms to gel or placebo, and found consistent benefits for sexual function and mood but no benefit for vitality or walking distance [s2] — improvements for men who were genuinely deficient, not a general enhancement. On safety, the TRAVERSE trial enrolled 5,246 men with or at high risk of cardiovascular disease and found no excess of heart attacks, strokes or cardiovascular deaths on testosterone against placebo [s1]. That is reassuring for men who need treatment; it is not a licence for men who do not, because it does not measure the costs that matter to a healthy young user.

The costs the trend understates

Two of those costs are central and routinely minimised. The first is fertility. Exogenous testosterone suppresses the body's own production and, with it, sperm production; the AUA guideline is explicit that clinicians must inform patients that testosterone therapy can impair spermatogenesis, and that men interested in future fertility should be counselled accordingly [s5]. For a young man with no deficiency, that is a large and often reversible-but-not-guaranteed price for a cosmetic goal.

The second is dependence in a physiological sense. Once external testosterone shuts down natural production, stopping can leave a man temporarily worse off than before he started — low, fatigued and reliant on continued dosing until his own axis recovers, if it does. The AUA guideline frames testosterone as a treatment for a diagnosed deficiency established on two separate morning measurements, precisely because starting it is not a trivially reversible experiment [s5]. Testmaxxing inverts that logic, treating the drug as an upgrade to be trialled rather than a therapy to be justified.

What to watch

The defensible kernel is that testosterone deficiency is a real condition with a real, evidence- based treatment. The trend's error is scope: applying a therapy validated in deficient, mostly older men to healthy young ones chasing a number, via supplements that do not work and online clinics built to say yes. Symptoms that might reflect low testosterone are a reason to be evaluated properly — with confirmed measurements and a discussion of fertility — not a reason to self-prescribe optimisation.

Sources

• [s1] Cardiovascular Safety of Testosterone-Replacement Therapy — New England Journal of Medicine, 16 June 2023. https://doi.org/10.1056/NEJMoa2215025
• [s2] Effects of Testosterone Treatment in Older Men — New England Journal of Medicine, 17 February 2016. https://doi.org/10.1056/NEJMoa1506119
• [s3] 'Testosterone Boosting' Supplements Composition and Claims Are not Supported by the Academic Literature — The World Journal of Men's Health, 17 June 2019. https://doi.org/10.5534/wjmh.190043
• [s4] Discordance Between Online Information and Male Hypogonadism Clinical Guidelines: A Global Multilingual Content Analysis — Journal of Clinical Endocrinology and Metabolism, 27 December 2025. https://doi.org/10.1210/clinem/dgaf689
• [s5] Evaluation and Management of Testosterone Deficiency: AUA Guideline — American Urological Association, 1 August 2018. https://www.auanet.org/guidelines-and-quality/guidelines/testosterone-deficiency-guideline